중공사 여과 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the hollow fiber filtration market size is expected to grow from USD 0.94 billion in 2025 to USD 1.07 billion in 2026 and is forecast to reach USD 2.09 billion by 2031 at 14.28% CAGR over 2026-2031.

This report is Segmented by Material (Synthetic Polymer and Ceramic), Technique (Microfiltration and Ultrafiltration), End User (Pharmaceutical & Biotechnology, and More), Application (Protein Concentration & Diafiltration, and More), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Hollow Fiber Filtration Market Trends and Insights

Rapid Expansion of Global Biologic Drug Pipeline

More than 6,500 monoclonal antibodies were in clinical development in 2025 versus 360 commercialized molecules in 2024, triggering a step-change in filtration run volumes and development batches. Each therapeutic candidate requires scalable filtration solutions through clinical and commercial phases, intensifying orders for flexible hollow fiber modules that switch quickly between development scales. Complex formats-bispecifics and antibody-drug conjugates-raise selectivity needs that conventional microfiltration cannot meet consistently, prompting ultrafiltration adoption. Most pipeline growth now stems from Asia-Pacific sponsors, driving suppliers to build local technical support and membrane production hubs to stay competitive. Technology providers therefore prioritize integrated systems combining membrane modules with in-line sensing to support process validation and comparability across global sites.

Rising Adoption of Single-Use Bioprocess Equipment

Global single-use system sales expanded at more than 10% CAGR between 2019-2024, and hollow fiber cartridges optimized for disposability are capturing the upside. Eliminating clean-in-place cycles lowers capital outlay and validation costs, making advanced filtration affordable for emerging biotechs and cell therapy developers. Investments by Cytiva and Pall totaling USD 1.5 billion-including USD 300 million earmarked for single-use lines-demonstrate supplier commitment to pre-sterilized, gamma-stable membrane assemblies. Uptake accelerates in greenfield Asian plants that can specify single-use architectures from day one. Environmental scrutiny over plastic waste, however, is spurring R&D into recyclable housings and compostable polymers, inserting sustainability criteria into procurement decisions.

Stringent Regulatory Validation and Documentation Requirements

FDA and EMA guidelines mandate exhaustive performance evidence for every membrane configuration, driving validation spend beyond USD 1 million per step on complex biologics. Smaller innovators lack specialized teams and often defer to CDMOs with proven filings, which slows direct equipment sales. Divergent regional rules-particularly around pre-use integrity testing-force dual studies, lengthening timelines by up to 18 months. Vendors with audit-ready data packages now enjoy preferential supplier status, but generating those dossiers is resource-intensive and raises barriers for new entrants.

Other drivers and restraints analyzed in the detailed report include:

1. Shift Toward Continuous and Perfusion Manufacturing
2. Surge in Advanced Therapy Commercialization
3. Membrane Fouling Leading to Recurrent Replacement Costs

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Synthetic polymers held 77.88% of hollow fiber filtration market share in 2025 thanks to mature supply chains and attractive unit costs. Within this cohort, polyethersulfone remains preferred for antibody purification owing to 4.52 L/m2*h*atm clean-water permeability and stable pH tolerance. Polyvinylidene fluoride gains in solvent-rich feeds, while polysulfone supports higher-pressure steps. Polypropylene persists where protein adsorption risk is low. Ceramic membranes, although still niche, are scaling at a 16.48% CAGR as plants seek longer life cycles and aggressive cleaning compatibility. Alumina and zirconia variants withstand caustic regimes and back-pulse procedures, reducing downtime in perfusion lines. Cost amortization over multi-year campaigns makes ceramics increasingly attractive as continuous processing expands, a trend that should raise their revenue share materially within the hollow fiber filtration market by 2031.

Microfiltration kept 61.72% revenue in 2025, driven by cell harvest and broth clarification tasks that fit its 0.1-0.45 µm cut-off range. Tangential-flow microfiltration (TFF) reigns in large-scale antibody plants, offering higher throughput than dead-end modes and proven regulatory lineage. The pivot to ultrafiltration, however, is unmistakable: at 16.55% CAGR, operators increasingly rely on 10-100 kDa membranes for buffer exchange and concentration, achieving >99.75% retention while trimming diafiltration volume. Single-pass configurations embedded in fully continuous platforms slash hold times and accelerate batch release testing, making ultrafiltration central to next-gen plant layouts. Suppliers differentiate via low-fouling chemistries and inline analytics that certify pore integrity in real time.

Complete Report Scope:

• By Material
  • Synthetic Polymer
    • Polyethersulfone (PES)
    • Polyvinylidene Fluoride (PVDF)
    • Polysulfone (PS)
    • Polypropylene (PP)
  • Ceramic
    • Alumina
    • Zirconia
• By Technique
  • Microfiltration
    • Dead-end
    • Tangential Flow (TFF)
  • Ultrafiltration
    • Dead-end
    • Tangential Flow (TFF)
• By End User
  • Pharmaceutical & Biotechnology
  • Contract/Clinical Research Organizations
  • Academic & Research Institutes
• By Application
  • Protein Concentration & Diafiltration
  • Cell Clarification / Harvest
  • Virus / VLP Production
  • Raw Material Filtration
  • Other Applications
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 40.88% of hollow fiber filtration market share in 2025 as decades of investment in Boston, San Francisco, and the Research Triangle reinforced a sophisticated supplier-user ecosystem. FDA guidance-clear on microbial retention, extractables, and integrity testing-speeds qualification of novel membrane chemistries. Fujifilm's USD 1.2 billion expansion in North Carolina adding 160,000 L of bioreactor volume exemplifies continued regional capacity growth.

Europe sustains a sizeable presence led by Germany's engineering strength and the United Kingdom's cell-and-gene therapy cluster. The EMA's environmental leanings promote ceramic membranes and reusable housings, while Horizon Europe funding channels pour capital into low-carbon bioprocess technologies. This policy framework both disciplines supplier claims and cultivates technology differentiation in sustainability metrics.

Asia-Pacific remains the fastest-growing area at 15.42% CAGR. China's biopharma market is forecast to exceed 1.4 trillion yuan by 2029, and state grants favor domestic membrane manufacturing scale-ups, trimming lead times for local biotech startups. South Korea emerges as a regional export hub, underscored by MilliporeSigma's EUR 300 million Daejeon plant that delivers sterile filtration consumables to a wider Asian customer base. Japan leverages precision ceramics expertise to supply ultra-smooth lumen surfaces for continuous lines, whereas Singapore positions itself as a regulatory sandbox for first-in-class filtration materials through fast-track approvals. Together these dynamics will gradually rebalance global revenue shares in the hollow fiber filtration market before 2030.

1. Repligen
2. Sartorius
3. Danaher
4. Asahi Kasei
5. Parker Hannifin
6. Koch Separation Solutions
7. Meissner Filtration Products
8. Merck Millipore (MilliporeSigma)
9. 3M
10. Alfa Laval
11. Microdyn-Nadir
12. Fresenius
13. W. L. Gore & Associates
14. Pentair
15. Toyobo Co., Ltd.
16. Sumitomo Electric Industries
17. Antylia Scientific
18. Mar Cor
19. Biotree

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rapid Expansion of Global Biologic Drug Pipeline
  • 4.2.2 Rising Adoption of Single-Use Bioprocess Equipment
  • 4.2.3 Shift Toward Continuous and Perfusion Manufacturing
  • 4.2.4 Growing Outsourcing to Contract Development and Manufacturing Organizations
  • 4.2.5 Surge in Advanced Therapy Medicinal Product Commercialization
  • 4.2.6 Emerging Demand for High-Purity Plant And Cultured Protein Processing
• 4.3 Market Restraints
  • 4.3.1 Stringent Regulatory Validation and Documentation Requirements
  • 4.3.2 Membrane Fouling Leading to Recurrent Replacement Costs
  • 4.3.3 High Capital Expenditure for Large-Scale Filtration Skids
  • 4.3.4 Performance Limitations with High-Viscosity Gene Vector Solutions
• 4.4 Regulatory Landscape
• 4.5 Porter's Five Forces Analysis
  • 4.5.1 Threat of New Entrants
  • 4.5.2 Bargaining Power of Buyers
  • 4.5.3 Bargaining Power of Suppliers
  • 4.5.4 Threat of Substitutes
  • 4.5.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Material
  • 5.1.1 Synthetic Polymer
    • 5.1.1.1 Polyethersulfone (PES)
    • 5.1.1.2 Polyvinylidene Fluoride (PVDF)
    • 5.1.1.3 Polysulfone (PS)
    • 5.1.1.4 Polypropylene (PP)
  • 5.1.2 Ceramic
    • 5.1.2.1 Alumina
    • 5.1.2.2 Zirconia
• 5.2 By Technique
  • 5.2.1 Microfiltration
    • 5.2.1.1 Dead-end
    • 5.2.1.2 Tangential Flow (TFF)
  • 5.2.2 Ultrafiltration
    • 5.2.2.1 Dead-end
    • 5.2.2.2 Tangential Flow (TFF)
• 5.3 By End User
  • 5.3.1 Pharmaceutical & Biotechnology
  • 5.3.2 Contract/Clinical Research Organizations
  • 5.3.3 Academic & Research Institutes
• 5.4 By Application
  • 5.4.1 Protein Concentration & Diafiltration
  • 5.4.2 Cell Clarification / Harvest
  • 5.4.3 Virus / VLP Production
  • 5.4.4 Raw Material Filtration
  • 5.4.5 Other Applications
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East & Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East & Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.3.1 Repligen Corporation
  • 6.3.2 Sartorius AG
  • 6.3.3 Danaher Corporation
  • 6.3.4 Asahi Kasei Co Ltd
  • 6.3.5 Parker Hannifin
  • 6.3.6 Koch Separation Solutions
  • 6.3.7 Meissner Filtration Products
  • 6.3.8 Merck Millipore (MilliporeSigma)
  • 6.3.9 3M Company
  • 6.3.10 Alfa Laval
  • 6.3.11 Microdyn-Nadir
  • 6.3.12 Fresenius Medical Care
  • 6.3.13 W. L. Gore & Associates
  • 6.3.14 Pentair
  • 6.3.15 Toyobo Co., Ltd.
  • 6.3.16 Sumitomo Electric Industries
  • 6.3.17 Antylia Scientific
  • 6.3.18 Mar Cor
  • 6.3.19 Biotree

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-Need Assessment